Analyst Viewpoint
Increase in elderly population and surge in approval and launch of new products are propelling the Guillain-Barre syndrome market size. Intravenous immunoglobulin is gaining traction in the treatment of Guillain-Barre syndrome as it helps halt the progression of the disease. Surge in funding for Guillain-Barre syndrome-related projects is also driving the market trajectory.
Major players operating in the global Guillain-Barre syndrome industry are focused on accelerating the product approval process and conducting research to discover novel medications. They are also acquiring new products to diversify their product offerings and increase their Guillain-Barre syndrome industry share.
Guillain-Barre Syndrome (GBS) is a relatively uncommon autoimmune illness. In this condition, the patient's immune system targets the nervous system. Peripheral neuropathy and GBS involve damage to peripheral nerves. The exact cause of GBS is unknown. Stomach flu and respiratory infections usually coincide with the syndrome. The neurological complications of Guillain-Barré syndrome include ascending muscle weakness, loss of reflexes, numbness, and tingling.
GBS symptoms include restricted eye or facial movements, high or low blood pressure, limb weakness, and breathing difficulties. Complex and multifaceted GBS leads to acute flaccid paralysis in children and adults. The diagnosis of Guillain-Barre syndrome is challenging in its early stages. The symptoms can vary from person to person and are similar to other neurological illnesses. Patients typically report tingling dysesthesias, mainly in the hands, and discomfort and limb weakness. Guillain-Barré syndrome can be effectively treated with plasma exchange. Analgesics, low-molecular-weight heparin, and anticonvulsants are also employed in the treatment of Guillain-Barré syndrome.
Aging increases the risk of immunological diseases including multiple sclerosis and severe motor axonal neuropathy. GBS affects people of all ages. However, it is more common in adults and males. Older patients with GBS are highly likely to have chronic comorbidities, which could lead to an incorrect diagnosis of the disease. According to the World Health Organization's 2021 updates, one in six persons worldwide is expected to be 60 years of age or older by 2030. Hence, rise in geriatric population is propelling the Guillain-barre syndrome market value.
The U.S. Food and Drug Administration’s quick medicine clearance program has resulted in a surge of new product approvals. In September 2019, Annexon Biosciences’ ANX005, a new medication for Guillain-Barré syndrome, was granted a fast-track designation by the U.S. Food and Drug Administration. ANX005 is designed to fully block C1q and the entire classical complement pathway to preserve the functioning synapses to slow or halt neurodegeneration.
According to the latest Guillain-Barre syndrome market trends, the intravenous immunoglobulin therapeutics segment held largest share in 2022. Intravenous immunoglobulin is a combination of antibodies (immunoglobulins) for the treatment of various medical conditions such as immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, HIV/AIDS, measles, and Guillain-Barré syndrome.
Immunoglobulins are injected under the skin, into a vein, or into a muscle, depending on the formulation. Various intravenous immunoglobulin medicines, such as Gamunex, Gammagard, and Privigen, are readily available.
According to the latest Guillain-Barre syndrome market analysis, North America dominated the industry in 2022. Presence of major vendors is fueling the market dynamics of the region. As per the June 2022 update from the Centers for Disease Control and Prevention (CDC), 3,000–6,000 people in the U.S. are diagnosed with GBS each year.
One of the most frequent causes of GBS is infection with Campylobacter jejuni, which causes diarrhea, according to an article published in June 2022 by the CDC. Moreover, GBS can affect people of any age, however, the risk is highest for those over 50 years of age.
Surge in funding for GBS-related projects is expected to spur the Guillain-Barre syndrome market growth in North America in the near future. In October 2021, co-investigators Brad Wright, Ph.D., Rebecca Traub, MD, and Chip Howard, MD received US$ 427,625 in funding from the National Institute of Neurological Disorders and Stroke (NINDS) for a project aimed at understanding Guillain-Barre syndrome through Medicare claims. The project is expected to be finished by February 2023.
Companies in the sector are implementing several strategies including mergers and acquisitions and new product development.
Grifols S.A, CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biological Products Holdings, Inc., Biotest AG, and Kedrion s.p.A. are key players operating in this market.
Each of this companies has been profiled in the Guillian-Barre syndrome market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 591.3 Mn |
| Market Forecast (Value) in 2031 | US$ 890.2 Mn |
| Growth Rate (CAGR) | 4.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 591.3 Mn in 2022
It is anticipated to grow at a CAGR of 4.7% from 2023 to 2031
Increase in elderly population and surge in approval and launch of new products
The intravenous immunoglobulin segment held the largest share in 2022
North America was the most lucrative region in 2022
Grifols S.A, CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd, Akari Therapeutics, PLC, China Biological Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Guillain-Barre Syndrome Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Guillain-Barre Syndrome Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Therapeutics
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapeutics, 2017–2031
6.3.1. Intravenous Immunoglobulin
6.3.2. Plasma Exchange
6.3.3. Others
6.4. Market Attractiveness Analysis, by Therapeutics
7. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospitals
8.3.2. Pharmacies
8.3.3. Retail Pharmacies
8.3.4. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Guillain-Barre Syndrome Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. South America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Guillain-Barre Syndrome Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Therapeutics, 2017–2031
10.3.1. Intravenous Immunoglobulin
10.3.2. Plasma Exchange
10.3.3. Others
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Parenteral
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospitals
10.5.2. Pharmacies
10.5.3. Retail Pharmacies
10.5.4. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Therapeutics
10.7.2. By Route of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Guillain-Barre Syndrome Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Therapeutics, 2017–2031
11.3.1. Intravenous Immunoglobulin
11.3.2. Plasma Exchange
11.3.3. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospitals
11.5.2. Pharmacies
11.5.3. Retail Pharmacies
11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Therapeutics
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Guillain-Barre Syndrome Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Therapeutics, 2017–2031
12.3.1. Intravenous Immunoglobulin
12.3.2. Plasma Exchange
12.3.3. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospitals
12.5.2. Pharmacies
12.5.3. Retail Pharmacies
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Therapeutics
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. South America Guillain-Barre Syndrome Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Therapeutics, 2017–2031
13.3.1. Intravenous Immunoglobulin
13.3.2. Plasma Exchange
13.3.3. Others
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospitals
13.5.2. Pharmacies
13.5.3. Retail Pharmacies
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of South America
13.7. Market Attractiveness Analysis
13.7.1. By Therapeutics
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Guillain-Barre Syndrome Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Therapeutics, 2017–2031
14.3.1. Intravenous Immunoglobulin
14.3.2. Plasma Exchange
14.3.3. Others
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospitals
14.5.2. Pharmacies
14.5.3. Retail Pharmacies
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Therapeutics
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Grifols S.A
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. CSL Behring LLC
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Shire plc
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Octapharma AG
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Nihon Pharmaceutical Co.,Ltd
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Akari Therapeutics, PLC
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. China Biological Products Holdings,Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Biotest AG
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Kedrion S.p.A
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017–2031
Table 02: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017–2031
Table 07: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 08: North America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017–2031
Table 11: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 12: Europe Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017–2031
Table 15: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: Asia Pacific Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017–2031
Table 19: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: South America Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2017–2031
Table 23: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 24: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Guillain-Barre Syndrome Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Therapeutics, 2022
Figure 03: Global Guillain-Barre Syndrome Market Value Share, by Therapeutics, 2022
Figure 04: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 05: Global Guillain-Barre Syndrome Market Value Share, by Route of Administration, 2022
Figure 06: Global Guillain-Barre Syndrome Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Guillain-Barre Syndrome Market Value Share, by Distribution Channel, 2022
Figure 08: Global Guillain-Barre Syndrome Market Value Share, by Region, 2022
Figure 09: Global Guillain-Barre Syndrome Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 11: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 12: Global Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 13: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 14: Global Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Guillain-Barre Syndrome Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Guillain-Barre Syndrome Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Guillain-Barre Syndrome Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 22: North America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 23: North America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 25: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 26: North America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 28: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 31: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 32: Europe Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 34: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 35: Europe Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 37: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 40: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 41: Asia Pacific Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 43: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 44: Asia Pacific Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: South America Guillain-Barre Syndrome Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 46: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: South America Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: South America Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 49: South America Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 50: South America Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 52: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 53: South America Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Guillain-Barre Syndrome Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 55: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 58: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 59: Middle East & Africa Guillain-Barre Syndrome Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Therapeutics, 2023–2031
Figure 61: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 62: Middle East & Africa Guillain-Barre Syndrome Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Guillain-Barre Syndrome Market
